主持多項(xiàng)抗癌新藥的Ⅰ、Ⅱ,、Ⅲ期臨床研究，參與國際多中心臨床研究工作40余項(xiàng),，目前承擔(dān)多項(xiàng)國家,、市級重大專項(xiàng)等課題研究，率先開展局部晚期乳腺癌光動(dòng)力治療的基礎(chǔ)與臨床研究,，開辟了光動(dòng)力轉(zhuǎn)化醫(yī)學(xué)研究新領(lǐng)域,，并獲2014年度天津科技進(jìn)步三等獎(jiǎng)。多次受邀參加國內(nèi)外學(xué)術(shù)會(huì)議大會(huì)發(fā)言,。國內(nèi)外發(fā)表論文80余篇,，主編論著1部。參與完成論著7部,。培養(yǎng)碩士研究生10余名,。
發(fā)表論文：
Ge J, Yu Y, Xin F, Yang ZJ, Zhao HM, Wang X, Tong ZS, Cao XC. Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.Cancer Sci. 2017 Feb 3.[Epub ahead of print]
Wang S, Li W, Wang F, Niu Y, Hao C, Wang X, He L, Tong Z. 36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified. Pathol Res Pract. 2017 Apr;213(4):310-315.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017 Mar;18(3):371-383.
Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016 Aug 9;7(32):52450-52459.
Shi YH, Dai DF, Li J, Dong YW, Jiang Y, Li HG, Gao Y, Chong CK, Li HY, Chu XQ, Yang C, Zhang Q, Tong ZS, Bai CG, Chen Y. Sulforaphane Analogues with Heterocyclic Moieties: Syntheses and Inhibitory Activities against Cancer Cell Lines. Molecules. 2016 Apr 21;21(4):514.
Zhang P, Tong Z, Tian F, Wang Y, Yang J, Li W, Di L, Liu W, Tang L, Qiu R, Xu B. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016 Aug 11;9(1):68.
Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, Gu K, Wang X, Xu B, Sun G, Chen H, Rukazenkov Y, Jiang Z.Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016 Aug 30;7(35):57301-57309.
Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016 Jun 14;7(24):35843-35852.
Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L. A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):23-7.
Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Oncol Rep. 2016 Mar;35(3):1483-92.
Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.
Wang C, Ju H, Shen C, Tong Z. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015 Sep 15;8(9):15648-56.
Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.
Lu N, Tong Z, Zhang M, Lu L, Cao H. Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):342-6.
Yuan P, Di LJ, Liu W, Wan DG, Dai H, Tong ZS, Du F, Xu BH. Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients. Int J Clin Exp Med. 2015 Feb 15;8(2):3072-9.
Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med. 2015 Oct;3(17):242.
Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015 Aug 28;8:2319-27.
Dong G, Jia Y, Wang X, Li S, Wang C, Shi Y, Tong Z. The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp Med. 2015 May 15;8(5):8283-7.
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):436-46.
Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015 Feb;45(2):146-52.
F Wang, Y Jia, Z Tong*. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor[J]. Jpn J Clin Oncol, 2015,45 (2): 146-152.
C Lu, W Wang, Y Jia, X Liu, Z Tong*, B Li*. Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells[J]. J Cell Biochem, 2014,115 (8): 1458-1466.
C Lu, LY Zhou, HJ Xu, XY Chen, Z Tong*, XD Liu, YS Jia, Y Chen. RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation[J]. Acta Pharmacol Sin, 2014,35 (7): 929-936.
Lu C, Xu H, Chen X, Tong Z, Liu X, Jia Y. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? Curr Oncol. 2013 Dec;20(6):e585-92
Wei XQ, Li X, Xin XJ, Tong ZS, Zhang S. Clinical features and survival analysis of very young (age<35) breast cancer patients. Asian Pac J Cancer Prev. 2013;14(10):5949-52.
Chen X, Liu X, Zhang L, Li S, Shi Y, Tong Z. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol. 2013 Oct;43(10):954-63.
He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF, Tong ZS. CHL1 is involved in human breast tumorigenesis and progression. Biochem Biophys Res Commun. 2013 Aug 23;438(2):433-8.
Z Guan, B Xu, ML DeSilvio, Z Shen, W Arpornwirat, Z Tong, V Lorvidhaya, Z Jiang, J Yang, A Makhson, WL Leung, MW Russo, B Newstat, L Wang, G Chen, C Oliva, H Gomez. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2013,31 (16): 1947-1953.
Q Zhang, Y Lu, Y Ding, J Zhai, Q Ji, W Ma, M Yang, H Fan, J Long, Z Tong, Y Shi, Y Jia, B Han, W Zhang, C Qiu, X Ma, Q Li, Q Shi, H Zhang, D Li, J Zhang, J Lin, LY Li, Y Gao, Y Chen. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells[J]. J Med Chem, 2012,55 (20): 8757-8769.
Z Tong*, P Miao, T Liu, Y Jia, X Liu. Enhanced antitumor effects of BPD-MA-mediated photodynamic therapy combined with adriamycin on breast cancer in mice[J]. Acta Pharmacol Sin, 2012,33 (10): 1319-1324.
L Zhang, C Hao, G Dong, Z Tong*. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China[J]. Breast Care (Basel), 2012,7 (1): 13-17.
C Hao, Y Shi, J Yu, X Wei, S Li, Z Tong*. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model[J]. Mol Cell Biochem, 2012,367 (1-2): 93-102.
J Li, X Liu, Z Tong*. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer[J]. Jpn J Clin Oncol, 2012,42 (6): 471-476.
C Hao, S Wei, Z Tong*, S Li, Y Shi, X Wang, ZH Zhu. The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro[J]. Tumour Biol, 2012,33 (4): 1159-1167.
T Liu, Z Tong*, L He, L Zhang. Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases[J]. Breast Care (Basel), 2011,6 (6): 446-451.
L Zhang, Z Tong*, S Li, X Ren, B Ren, X Wang, S Cao, C Wang, L He. Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients[J]. Breast Care (Basel), 2009,4 (6): 379-386.
Zhang L, Hao C, Dong G, Tong Z. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care (Basel). 2012 Feb;7(1):13-17. Epub 2012 Feb 13.
Li J, Liu X, Tong Z. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. Jpn J Clin Oncol. 2012 Jun;42(6):471-6. Epub 2012 Apr 3.
Hao C, Shi Y, Yu J, Wei X, Li S, Tong Z. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model. Mol Cell Biochem. 2012 Aug;367(1-2):93-102. doi: 10.1007/s11010-012-1323-x. Epub 2012 May 1.
Hao C, Wei S, Tong Z, Li S, Shi Y, Wang X, Zhu ZH. The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro. Tumour Biol. 2012 Aug;33(4):1159-67.
Zhang Q, Lu Y, Ding Y, Zhai J, Ji Q, Ma W, Yang M, Fan H, Long J, Tong Z, Shi Y, Jia Y, Han B, Zhang W, Qiu C, Ma X, Li Q, Shi Q, Zhang H, Li D, Zhang J, Lin J, Li LY, Gao Y, Chen Y.Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012 Oct 25;55(20):8757-69.
Liu T，Tong Z,，He L,，Zhang L. Clinicopathological Characteristics and Survival Analysis of 87 Male Breast Cancer Cases. 2011，6:446-451
Overall Survival Benefit Observed with Lapatinib(L) plus Paclitaxel(P) as First-line therapy in patients with HER2-overexpressing metastatic breast cancer .33rd Annual San Antorio Breast Cancer Symposium December 8-12 2010 San Antorio TX USA
國產(chǎn)托烷司瓊治療由順鉑引起惡心嘔吐的臨床觀察佟仲生中國腫瘤臨床2005,；14,；832-834
GP與NP方案治療對蒽環(huán)類及紫杉類耐藥轉(zhuǎn)移性乳腺癌的療效觀察佟仲生(通訊作者)實(shí)用癌癥雜志2009；24卷4期P366-369
重組血管內(nèi)皮抑素Ⅰ期臨床研究佟仲生中華現(xiàn)代內(nèi)科學(xué)雜志2006 VOL3 1150-1155
注射用奈達(dá)鉑治療頭頸部鱗癌與食管癌及難治非小細(xì)胞肺癌Ⅱ期臨床試驗(yàn)研究佟仲生(第一作者)腫瘤防治研究雜志2005 VOL 12 No23 1779-1784
芬太尼透皮貼劑在中度癌痛治療中的臨床觀察佟仲生(第三作者)中國腫瘤臨床2006 VOL 33 577-579
芬太尼透皮貼劑與硫酸嗎啡控釋片治療中重度慢性癌痛療效及不良反應(yīng)臨床觀察佟仲生(第二作者)天津醫(yī)科大學(xué)學(xué)報(bào)2005VOL 11 NO4 586-589
張麗,，趙曉輝,，佟仲生等. 356例三陰性乳腺癌的臨床特征及預(yù)后多因素分析中國腫瘤臨床2010,37(18):1045-49.
張麗，佟仲生,，李淑芬等.自體外周血造血干細(xì)胞移植聯(lián)合大劑量化療的高危乳腺癌患者生活質(zhì)量分析中華乳腺病雜志(電子版) 2010,4(3):32-38.
苗培田,，佟仲生，張麗等.年齡因素對三陰乳腺癌患者預(yù)后的影響,；中國腫瘤臨床2010,37(22)：1304-1308.
苗培田，佟仲生(通訊作者),，郝春芳等.三陰乳腺癌120例臨床及預(yù)后分析,；中華醫(yī)學(xué)雜志2010,90(40)：2848-2851.
劉婷婷，佟仲生(通訊作者)等,，男性與女性乳腺癌預(yù)后因素的生存分析《中華醫(yī)學(xué)雜志》2010,90(44):3135-3139.
劉婷婷,，佟仲生(通訊作者)等,，81例男性乳腺癌臨床特征及生存分析《實(shí)用腫瘤雜志》2010,25(5):564-568
佟仲生，王曉蕊等,，骨膠原代謝指標(biāo)在乳腺癌骨轉(zhuǎn)移診斷中的應(yīng)用,，2010 30(5)
劉曉東，汪旭,，賈勇圣,，王蕊，佟仲生.三陰性對小腫塊乳腺癌患者預(yù)后的影響.中國腫瘤臨,，2012 Vol. 39 (9): 578-582
于倩;佟仲生;汪旭;史業(yè)輝;何麗宏;劉曉東.轉(zhuǎn)移性乳腺癌臨床病理特征及預(yù)后分析[J]腫瘤.2012,(08)
李軍楠,、劉曉東、董國雷,、佟仲生. 2342例乳腺癌患者臨床病理學(xué)特征及預(yù)后分析,中國腫瘤臨床2012年39卷05期
張麗;佟仲生;李淑芬;史業(yè)輝;郝春芳.紫杉醇脂質(zhì)體對卵巢癌細(xì)胞生長抑制作用的實(shí)驗(yàn)研究[J]實(shí)用腫瘤雜志.2012,(01)
史業(yè)輝,賈勇圣,佟仲生.人肝癌細(xì)胞線粒體DNA變異研究.中華實(shí)驗(yàn)外科雜志2012.10
賈勇圣,，劉曉東，史業(yè)輝,，董國雷,，佟仲生. KLF4對肝癌細(xì)胞HepG2化療和光動(dòng)力治療的調(diào)節(jié)作用.中國腫瘤生物治療雜志，2012,，(4) ：397~401
邱梅清,、佟仲生、賈勇圣,、董國雷,、郝春芳.老年性乳腺癌預(yù)后多因素分析，實(shí)用腫瘤雜志,，2012.
邱梅清,，佟仲生，郝春芳,，賈勇圣,，劉曉東.乳腺癌首發(fā)肺轉(zhuǎn)移預(yù)后多因素分析，腫瘤,，2012.
邱梅清,、佟仲生、賈勇圣,、劉曉東,、陳悅.線粒體融合素基因-2過表達(dá)對小白菊內(nèi)酯治療乳腺癌敏感性的影響，中國腫瘤生物治療雜志,，2012.
路燦,，佟仲生，賈勇圣.腫瘤鐵代謝研究進(jìn)展，生理科學(xué)進(jìn)展,，2012
劉婷婷,，佟仲生，史業(yè)輝,，郝春芳.選擇性COX-2抑制劑對人乳腺癌細(xì)胞MCF-7的抑制作用及分子機(jī)制研究.中國腫瘤臨床,，2011，38(5)
沈春燕,，穆海玉,，王忱，多健,，佟仲生. APE1,、VEGF在非小細(xì)胞肺癌組織中的表達(dá)及其與預(yù)后的關(guān)系.天津醫(yī)科大學(xué)學(xué)報(bào)，2011,，17(2)
沈春燕,，穆海玉，佟仲生.葡萄糖轉(zhuǎn)運(yùn)蛋白1在乳腺癌組織中的表達(dá)及與其預(yù)后的關(guān)系.實(shí)用癌癥雜志,，2011,，26(6)
苗培田，佟仲生,，郝春芳,，張萌.不同亞型轉(zhuǎn)移性乳腺癌轉(zhuǎn)移特點(diǎn)及預(yù)后分析.中國腫瘤臨床，2011,，38(4)
李軍楠,，劉曉東，佟仲生. T1micN0M0,、T1aN0M0和T1bN0M0乳腺癌376例臨床特征和預(yù)后分析.腫瘤,，2011，31(11)
劉曉東,，佟仲生,，李淑芬，史業(yè)輝,，汪旭,，郝春芳.局部晚期乳腺癌1081例臨床病理特征及預(yù)后分析，腫瘤,，2011,，31 (10)
|
